Cyclopharm Limited 2024 Performance & Growth Outlook.

Cyclopharm Limited’s (ASX: CYC) 2024 performance highlighted significant growth in Technegas adoption and third-party distribution. The company reported record sales revenue of AU$27.6 million, a 5% increase from the prior corresponding period (pcp), driven by strong global Technegas sales and initial U.S. market penetration. U.S. sales of Technegas totaled AU$827,000, with a 131% growth in the second half, supported by early adoption from key opinion leaders. The company successfully raised AU$20 million through a capital raising and an additional AU$4 million via a share purchase plan, maintaining a strong cash position of AU$20.6 million at year-end. 

Technegas is now installed in 66 countries, including 17 U.S. sites in 2024. Regulatory renewals were maintained across all markets, and the "Beyond PE" strategy continues to expand with clinical trials such as a French study on residual pulmonary vascular obstruction. Looking ahead, secured U.S. sales and reimbursement support from CMS position Cyclopharm for continued growth in 2025.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com